FUSN Stock Overview
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines.
Fusion Pharmaceuticals Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.27|
|52 Week High||US$8.73|
|52 Week Low||US$1.98|
|1 Month Change||-1.30%|
|3 Month Change||-6.64%|
|1 Year Change||-51.70%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-86.65%|
Recent News & Updates
Fusion Pharmaceuticals initiated at buy at Truist on lead candidate for solid tumorsSep 16
Fusion Pharma doses first patient in phase 1/2 study for solid tumors treatmentAug 29
Will Fusion Pharmaceuticals (NASDAQ:FUSN) Spend Its Cash Wisely?Aug 10
We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn RateJan 16
We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn RateAug 28
We're Hopeful That Fusion Pharmaceuticals (NASDAQ:FUSN) Will Use Its Cash WiselyApr 05
How Much Of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Do Institutions Own?Mar 01
Who Has Been Buying Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Shares?Jan 25
Here's Why We're Not Too Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn SituationDec 21
|FUSN||US Biotechs||US Market|
Return vs Industry: FUSN underperformed the US Biotechs industry which returned -7.4% over the past year.
Return vs Market: FUSN underperformed the US Market which returned -14.9% over the past year.
|FUSN Average Weekly Movement||12.7%|
|Biotechs Industry Average Movement||11.2%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: FUSN is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: FUSN's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor.
Fusion Pharmaceuticals Inc. Fundamentals Summary
|FUSN fundamental statistics|
Is FUSN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|FUSN income statement (TTM)|
|Cost of Revenue||US$53.10m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.79|
|Net Profit Margin||-4,189.61%|
How did FUSN perform over the long term?See historical performance and comparison